Skip to content
Biotechnology

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash University 2 mins read

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together. 

Surgeons routinely use stainless steel or titanium, which stay in the body forever, can cause discomfort and may require follow-up surgeries. A new zinc alloy, designed by Monash biomedical engineers, could solve these problems by being mechanically strong but gentle enough to degrade safely over time while supporting optimal healing.

A study published today in Nature shows the research team’s innovative approach to making the zinc alloy as strong as permanent steel implants and more durable than other biodegradable options like magnesium-based implants.

Lead researcher, Professor Jian-feng Nie, from the Department of Materials Science and Engineering, said the innovative material had the potential to transform orthopaedic care by reducing complications, minimising the need for additional surgeries, and offering a sustainable alternative to permanent metallic implants.

“Our zinc alloy material could revolutionise orthopaedic care – opening the door to safer, smaller implants that not only enhance patient comfort but also promote better healing outcomes by minimising disruption to surrounding tissues,” Professor Nie said.

“An implant that never disappears will always be a risk to the patient. On the other hand, one that degrades too fast won’t allow adequate time for the bones to heal. With our zinc alloy material, we can achieve the optimal balance between strength and controlled degradation of the implant to promote better healing.”

The research shows that by engineering the size and orientation of the material’s grains, the zinc alloy can bend and adapt in unique ways to accommodate the shapes of its neighbouring tissues. 

“This made it not only stronger but more flexible, offering a game-changing alternative for orthopaedics,” Professor Nie said.

The research is paving the way for a new start-up to be launched out of Monash University with a focus on developing next-generation biodegradable implants.

https://doi.org/10.1038/s41586-024-08415-8

-ENDS-

MEDIA ENQUIRIES:

Courtney Karayannis, Media and Communications Manager

Monash University

T: +61 408 508 454 or [email protected] 



Monash University Media | +613 9903 4840 | [email protected] 

Visit Monash Lens for expert insights and commentary

 

Media

More from this category

  • Biotechnology
  • 06/06/2026
  • 08:05
AusBiotech

Opposition to proposed R&D Tax Incentive change unites Australia’s biotech, medtech and health tech sector

6 June 2026 Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas. Nine leading health and life sciences organisations: AusBiotech, Pathology Technology Australia, MTPConnect, ANDHealth, Life Sciences Queensland, Life Sciences WA, BioNSW, BioMelbourne Network and ARCS Australia, have co-signed a letter to Treasurer Jim Chalmers asking for an urgent review of RDTI changes proposed in the Federal Budget. While the sector shares concerns regarding a number of tax changes including to CGT, a proposal to limit the RDTI’s long standing…

  • Biotechnology
  • 04/06/2026
  • 06:17
Iovance Biotherapeutics, Inc.

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. Amtagvi is indicated for the treatment of adult patients with…

  • Biotechnology, Medical Health Aged Care
  • 29/05/2026
  • 08:44
Denteric

Denteric Commences a Phase I Safety Study in Patients with Early Alzheimer’s Disease

Melbourne, Australia — Denteric today announced the commencement of participant recruitment for a Phase I clinical study of its first-in-class therapy for Alzheimer’s disease. Alzheimer’s disease remains one of the greatest medical challenges of our time and with an aging population this will only increase. Approximately 38 million people globally and 7 million in the US alone live with Alzheimer’s disease. A growing body of research links the progression of Alzheimer’s disease with exposure to chronic bacterial and viral infections. Porphyromonas gingivalis, a bacterium that commonly infects tooth pockets and causes chronic inflammation, has been shown to release toxic proteins…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.